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In patients with gastroesophageal reflux disease, persistent symptoms on proton pump inhibitor (PPI) therapy may be due to 
residual acid or non-acid reflux. Combined impedance-pH has been suggested to be superior to pH alone in the management 
of refractory patients to PPI. The utility of implementation of this technique in every day clinical practice is still unknown. The 
aim of this study was to investigate the outcomes of patients studied with combined impedance-pH and to evaluate the yield 
of additional impedance monitoring over pH alone in patients with persistent gastroesophageal reflux disease symptoms.
Methods
Seventy-one patients (31 men; mean age, 49.1 ± 15.5 years) on PPI therapy underwent combined impedance-pH for persis-
tent typical (76%) or atypical (49%) symptoms. 
Results
During impedance-pH study, 44 (62%) patients reported symptoms. A positive symptom index (SI) was found in 21 (48%) pa-
tients: 8 (18.2%) had a positive SI for acid reflux, 9 (20.5%) for non-acid reflux and 4 (9.1%) for mixed reflux. Addition of 
impedance allowed association between reflux and symptoms in 20.5% of patients who would have been missed by pH study 
alone. Heartburn was the most prevalent symptom associated with acid reflux, whereas regurgitation and ear, nose and throat 
symptoms were associated with non-acid reflux.
Conclusions
The use of combined impedance-pH monitoring substantially increased the diagnostic yield compared to pH alone. With SI 
analysis, 20.5% of patients received a diagnosis that could not have been achieved with pH testing alone. 
(J Neurogastroenterol Motil 2011;17:158-163)
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Introduction
Gastroesophageal reflux disease (GERD) is a common dis-
order affecting approximately 35%-40% of the adult popu-
lation.
1,2 Proton pump inhibitors (PPIs) are the most potent 
agents for acid suppression and standard dose (once daily) of dif-
ferent PPIs has been established as providing symptom relief and 
healing of lesions in the majority of patients.
3-6 Some patients re-
quire twice-daily PPI therapy, but may continue to experience 
GERD symptoms.
6,7 It has been estimated that about 40% of 
GERD patients remain symptomatic despite treatment with 
PPIs.
8 In these patients, ongoing symptoms may be caused by 
persistent acid reflux due to insufficient inhibition of gastric acid 
production, by “non-acid” reflux or by other causes that can be 
misinterpreted as GERD.
9-12
In patients with persistent GERD symptoms despite acid 
suppression, current management algorithms propose pH mon-
itoring under PPIs.
13 However, recent studies challenged this 
approach showing that ambulatory pH monitoring has a low like-
lihood to be positive in this setting.
14,15 The recently developed 
combined impedance-pH technology represents a better tool un-
der these circumstances because it detects reflux of all types.
10 
Impedance monitoring has the ability to detect reflux episodes in-
dependent of the pH of the refluxate and concomitant pH re-
cording determine their acidity classifying them as acidic or 
non-acidic. As non-acid reflux is considered a putative cause of 
ongoing symptoms despite PPI therapy, combined impedance- 
pH monitoring seems to be the best strategy for evaluation of 
persistent reflux. It provides the same information as traditional 
pH monitoring and adds to it relevant information on the preva-
lence of non-acid reflux and its relation to refractory GERD 
symptoms.
The aim of our study was to evaluate the added yield of im-
pedance-pH monitoring compared with conventional pH-metry 




We analyzed 24 hour combined impedance-pH studies in 
patients who experienced persistent GERD-related symptoms 
while on PPI therapy. In addition, the daily dose of PPI 
(standard or double dose) and the presence of typical and atypical 
symptoms were analyzed in all patients. Heartburn, regurgitation 
and chest pain were considered typical symptoms, whereas pul-
monary and ear, nose and throat (ENT) symptoms were included 
in atypical symptoms. All patients had a normal upper endoscopy. 
The study protocol was approved by the Attikon University 
General Hospital Institutional Review Board.
Ambulatory Impedance-pH Monitoring
A 6-channel impedance catheter (outer diameter 2.3 mm) 
with attached pH recording at 5 cm above the manometrically lo-
calized lower esophageal sphincter was used. Before each study, 
the catheter was calibrated in buffer solutions of pH 7 and 4. For 
intraluminal impedance, the catheter enabled recordings from 6 
segments, each recording segment being 2 cm. The recording 
segments were located at 2-4, 4-6, 8-10, 10-12, 14-16 and 17-19 
cm above the manometrically localized LES. The pH and im-
pedance signals were stored in a digital system (Omega, MMS, 




All patients underwent an upper endoscopy, followed by sta-
tionary esophageal manometry. Ambulatory 24 hour esophageal 
impedance-pH was performed on one of the next 7 days. Patients 
were required to be fasting for at least 6 hours before the 
procedure. Treatment with PPI was continued; all other drugs 
potentially affecting gastrointestinal motility and gastrointestinal 
secretion were discontinued at least 1 week prior to the study.
Data collection device, worn in a belt on the patient’s waist, 
was connected to the catheter that had been introduced via 
nostril. Patients returned to their home and were instructed to 
continue their daily activities during the 24 hour measurement 
period. They were also asked to record a timetable of their meals 
and of time spending in upright and supine position on a diary 
card. Moreover, the occurrence of any symptom was recorded on 
patients’ diary card. 
Data Analysis
Combined impedance-pH data collected included any type 
of reflux episodes.  For the analysis, the periods of meal con-
sumption were marked and excluded. Reflux events were identi-
fied based on previously described criteria and classified as acidic 
or non-acidic using a threshold of pH = 4.
9,10 The symptom in-
dex (SI) was calculated for each patient in relation to acid and Georgios Karamanolis, et al
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Table 1. Reflux Parameters and Symptoms of Symptomatic Patients on






Number (%) 30 (71.4) 14 (42.3) 0.048
Age (yr) 48.1 ± 14.5 50.0 ± 15.7 0.249
Gender (male/female) 14/16 5/9 0.245
Total number of reflux 41.3 ± 20.0 33.6 ± 18.9 0.229
Number of acid reflux 14.3 ± 13.7 11.6 ± 8.4 0.416
Percentage of time pH < 4 5.5 ± 9.1 4.3 ± 7.6 0.662
Heartburn (n [%])
Regurgitation (n [%])




9( 5 0 )
2( 3 3 . 3 )




ENT symptoms (n [%])
Pulmonary symptoms (n [%])
11 (78.6)
8 (61.5)
2( 6 6 . 7 )
1( 1 6 . 7 )
0.659
0.068
PPI, proton pump inhibitor; ENT, ear, nose and throat.
Table 2. Demographic Characteristics and Symptoms Reported by 
Patients With and Without Positive Symptom Index 
SI (+)  SI (−) P-value
 Number 21 23
 Age (yr) 48.1 ± 14.5 50.0 ± 15.7 0.680
 Gender (male/female) 10/11 10/13 0.782





































SI, symptom index; PPI, proton pump inhibitor; ENT, ear, nose and 
throat.
non-acid reflux episodes. A symptom was considered to be asso-
ciated with reflux if it was preceded within 2 minutes by a reflux 
episode.
17 A positive SI was defined if > 50% of the symptoms 
were associated with reflux.
18 Impedance-pH monitoring was 
considered pathological when a positive SI was present.
Statistical Methods
Values are expressed as mean ± SD. Statistical analysis was 
performed by Student’s t test or Chi-square testing wherever 




Seventy-one patients (31 men; mean age, 49.1 ± 15.5 years) 
with refractory reflux symptoms underwent a 24 hour combined 
impedance-pH monitoring under PPI therapy. Forty-two (59%) 
patients were treated with standard PPI dose and 29 (41%) with 
double PPI dose. Fifty-four (76%) patients had typical symp-
toms, while 35 (49%) patients had atypical symptoms. 
Impedance-pH Monitoring
Forty-four (62%) patients reported symptoms during the 24 
hour impedance-pH study; 30 patients were on standard and 14 
on double PPI dose. Heartburn (34%) was the most common 
symptom reported, following by ENT and regurgitation (19%, 
respectively) while chest pain and pulmonary symptoms were re-
ported by 14% of patients. 
Standard vs Double Proton Pump Inhibitor Dose
The proportion of patients reporting symptoms were higher 
in those on standard PPI compared to those on double dose 
(30/42 vs 14/29, P = 0.048). The age and sex were similar be-
tween patients on standard and on double PPI dose (Table 1). 
Among symptoms, regurgitation and pulmonary symptoms were 
reported more frequent by patients on once PPI daily, although 
the difference was not statistically significant. The percentage 
time of a pH < 4 was similar in patients on standard compared to 
those on double PPI dose (5.5 ± 9.1 vs 4.3 ± 7.6, respectively). 
There was no statistically significant difference in the mean num-
ber of total reflux episodes that occurred during the study (41.3 
± 20.0 on standard dose vs 33.6 ± 18.9 on double dose, P = 
0.220) and in the mean number of acid reflux episodes (14.3 ± 
13.7 on standard dose vs 11.1 ± 8.4 on double dose, P = 0.416), 
as well. 
Symptom Index Analysis
From 44 patients, a positive SI for at least 1 of patients’ 
symptom was found in 21 (48%) patients. Eleven (52%) patients 
had a positive SI for 1 symptom, 8 (38%) patients for 2 and 2 pa-
tients (10%) for 3 symptoms. The PPI medication dose was sim-
ilar between patients with and without positive SI (Table 2). 
Heartburn was the most prevalent symptom associated with re-
flux episodes, followed by regurgitation and ENT symptoms Impedance-pH in Refractory Reflux 
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Typical (n) 34 6 11
Heartburn 24 6 5
Regurgitation 13 2 5
Chest pain 9 1 3
Atypical (n) 21 4 6
ENT 13 2 5
Pulmonary 9 2 1
SI, symptom index; ENT, ear, nose and throat.
Figure. Combined impedance-pH monitoring in 71 patients on proton
pump inhibitor therapy. SI, symptom index.
(Table 2). Regarding the frequency of reported symptoms in pa-
tients with or without positive SI, there was no statistically sig-
nificant difference between typical and atypical symptoms as a 
whole and among any of the individual symptoms. 
Of the 21 patients with an overall positive SI, 8 (18.2%) had 
a positive SI for acid reflux, 9 (20.5%) for non-acid reflux and 4 
(9.1%) for mixed reflux (Figure). Thus, addition of impedance 
allowed association between reflux and symptoms in 20.5% of pa-
tients who would have been missed by a pH study alone. 
Evidence consistent with acid reflux as a cause of symptoms was 
found in 27.3% of patients, whereas a temporal association be-
tween non-acid reflux and symptoms was present in 29.6% of 
patients. As indicated in Table 3, heartburn was the most preva-
lent symptom associated with acid reflux, whereas regurgitation 
and ENT symptoms were associated with non-acid reflux.
Discussion
In patients with GERD symptoms refractory to PPI therapy, 
24 hour pH testing is still considered the gold standard method 
to diagnose reflux.
13 However, recent studies challenged this ap-
proach showing that ambulatory pH monitoring in patients re-
fractory to PPI therapy was most likely to be normal.
14,15 
Combined impedance-pH monitoring has recently received 
worldwide interest because of its ability to detect not only acid but 
also all types of reflux. As the main concern in patients with re-
fractory symptoms to PPI is whether or not their symptoms are 
brought about by reflux, we used SI as the method that can estab-
lish a correlation between reflux and symptoms. 
Our results showed that 48% of patients on PPI therapy had 
a positive SI for all types of reflux. A positive SI for acid reflux 
was found in only 27.3% of these patients. In our population, 
non-acid reflux was considered as the cause of symptoms in 
20.5% of patients. Thus, before the advent of combined im-
pedance-pH, this proportion of patients would have been identi-
fied as negative for GERD and represents the increased diag-
nostic yield of this technique compared with pH study alone. Our 
results are similar to a multicenter study of 168 refractory GERD 
patients, in which a positive SI for non-acid reflux was found in 
37%.
11 A French-Belgian cohort study also revealed that the ad-
dition of impedance resulted in a considerable overall diagnostic 
gain of 16.7% in patients on PPI.
12 In addition, a recent study 
showed that 39% of patients on double daily PPI therapy had a 
positive SI for non-acid reflux and would have been mis-
diagnosed by a pH-alone study.
19 The combination of conven-
tional pH monitoring with impedance was also helpful in identi-
fying non-erosive reflux disease patients off the medication who 
had a positive symptom association for non-acid reflux. Without 
impedance addition, this subgroup of patients would have been 
labelled as having functional heartburn.
20 In a recently published 
study, Blonski et al
21 underlined the clinical importance of 
non-acid reflux showing that the maximal rate of reflux episodes 
was the same whether patients were taking medication or not.
Heartburn has traditionally been accepted as the most fre-
quent acid-mediated symptom, and we indeed found that heart-
burn was the most prevalent symptom associated with acid reflux. 
Regurgitation and ENT symptoms were the most common man-
ifestations in patients with non-acid reflux. In the literature there 
was conflicting results regarding regurgitation; Zerbib et al
12 re-
ported a positive association of regurgitation and non-acid reflux, 
while Kline et al
22 found that regurgitation accounted for 64% of 
symptoms in the acid-reflux group of patients. For ENT symp-
toms, it is widely accepted that it is unlikely to related with acid Georgios Karamanolis, et al
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reflux.
23 Non-acid reflux triggering ENT symptoms is a concept 
that has gained interest and our results support the hypothesis 
that non-acid reflux could be the cause of ENT symptoms. 
Although our finding is very promising, we should keep in mind 
that the cause and effect relationship between atypical symptoms 
and reflux is difficult to be established. Thus, a study including 
more patients should have to confirm our results, as only a minor-
ity of our patients had ENT symptoms.
Once GERD has been established as a diagnosis, the next 
step will be to determine the response to various therapies for the 
patient. In patients with pathological acid exposure, a shift to a 
different PPI, an addition of a nighttime histamine-2 receptor 
antagonist or increase of PPI dose could yield a better response 
rate.
24,25 In patients with non-acid or mixed reflux potential thera-
pies would include medical therapies, such as baclofen, endo-
scopic therapy and surgical treatment. 
Our study showed that 52% of patients reporting symptoms 
during the impedance-pH monitoring  did not have evidence of an 
association of GERD-like symptoms with any type of reflux 
events. This information has clinical importance because this 
finding indicates that other causes, such as functional disorders of 
the esophagus or hypersensitivity to different stimuli, should be 
investigated. Our results are similar to previously published stud-
ies; a proportion of patients (ranged from 19% to 58%) who ex-
perienced symptoms during the study day had no evidence con-
sistent with reflux as a cause of these symptoms.
12,19-22 
A limitation of our study is the fact that our study population 
was a mixed cohort regarding medication use, with 59% on single 
dose of PPI. Thus, someone can argue that these patients may 
not represent the standard patient who should undergo further 
investigation with 24 hour impedance-pH monitoring. However, 
population of patients included in the study is representative of 
every day patients referred to our unit with symptoms presumed 
due to GERD. 
In conclusion, our study showed that combined impedance- 
pH monitoring significantly increased the diagnostic yield of per-
sistent pathological reflux compared to pH alone in GERD pa-
tients refractory to PPI therapy. With SI analysis, 20.5% of pa-
tients received a diagnosis that could not have been achieved with 
pH testing alone. 
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